Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avenue TherapeuticsATXI -15.11%34 EV-to-EBITDA is 0.36 as of Aug. 10, 2026, which is 44% below its 10-year median of 0.64. GuruFocus rates ATXI with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 400 Biotechnology companies, Avenue Therapeutics ranks better than 85.5% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Avenue Therapeutics's enterprise value is $-1.10 Mil.
Avenue Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-3.10 Mil. Therefore, Avenue Therapeutics's EV-to-EBITDA for today is 0.36.
The historical rank and industry rank for Avenue Therapeutics's EV-to-EBITDA or its related term are showing as below:
ATXI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.12 Med: 0.64 Max: 0.77
Current: 0.53
During the past 11 years, the highest EV-to-EBITDA of Avenue Therapeutics was 0.77. The lowest was 0.12. And the median was 0.64.
ATXI's EV-to-EBITDA is ranked better than 85.5% of 400
companies
in the Biotechnology industry
Industry Median: 13.065
vs ATXI: 0.53
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Avenue Therapeutics's PE Ratio (TTM) for today is calculated as:
Avenue Therapeutics's share price for today is $0.2551.
Avenue Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.850.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Avenue Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Avenue Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avenue Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Avenue Therapeutics's EV-to-EBITDA falls into.
Avenue Therapeutics's current Enterprise Value is $-1.10 Mil.
Avenue Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avenue Therapeutics (ATXI) has a EV-to-EBITDA of 0.36 as of Aug. 10, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Avenue Therapeutics. This is 44% below median its historical median of 0.64. Over the past decade, Avenue Therapeutics' EV-to-EBITDA has ranged from 0.12 to 0.77. According to the industry distribution chart, Avenue Therapeutics ranks #58 out of 400 companies in the Biotechnology industry, placing it in the top 14.5%.
Is Avenue Therapeutics' EV-to-EBITDA too high?
Avenue Therapeutics' current EV-to-EBITDA of 0.36 is 44% below median its 10-year median of 0.64. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 0.77. The Biotechnology industry median EV-to-EBITDA is 13.07. Avenue Therapeutics' value of 0.36 is 97.2% below this industry median. Based on the distribution chart, Avenue Therapeutics ranks #58 out of 400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Avenue Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Avenue Therapeutics' EV-to-EBITDA compare to LYRA and ZVSA?
According to the Biotechnology industry distribution chart, Avenue Therapeutics ranks #58 out of 400 companies for EV-to-EBITDA. This places Avenue Therapeutics in the top 15% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.07. Avenue Therapeutics' value of 0.36 is 97.2% below this benchmark. Historically, Avenue Therapeutics' own EV-to-EBITDA has ranged from 0.12 to 0.77 over the past decade. While the company's 10-year median is 0.64 vs. the industry median of 13.07, Avenue Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.07, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avenue Therapeutics's current EV-to-EBITDA of 0.36 is 97.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Avenue Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avenue Therapeutics's current EV-to-EBITDA is 0.36, which is 44% below median its own 10-year median of 0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avenue Therapeutics stock overvalued right now?
Avenue Therapeutics (ATXI) has a current EV-to-EBITDA of 0.36. The current EV-to-EBITDA is 0.36, which is 44% below median its 10-year median of 0.64 and 97.2% below the Biotechnology industry median of 13.07. Avenue Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Avenue Therapeutics (ATXI), the current EV-to-EBITDA is 0.36 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It is focused on advancing impactful therapies with the potential to overcome limitations of existing treatment options and ultimately transform patient outcomes. Current product candidates include ATX-04, a selective beta adrenergic agonist for Pompe disease, intravenous tramadol (IV tramadol), a Schedule IV opioid for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. The company operates in one reportable segment, the development and commercialization of therapies for the treatment of neurologic diseases.
34GF Score
Get the complete analysis for ATXI
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATXI has been successfully added to your 
